作者：
Martin J,Connor [1]
;
Mesfin,Genie [2]
;
Tim,Dudderidge [3]
;
Hangjian,Wu [4]
;
Johanna,Sukumar [5]
;
Mark,Beresford [6]
;
Diletta,Bianchini [7]
;
Chee,Goh [8]
;
Gail,Horan [9]
;
Pasquale,Innominato [10]
;
Vincent,Khoo [11]
;
Natalia,Klimowska-Nassar [12]
;
Sanjeev,Madaan [13]
;
Stephen,Mangar [14]
;
Stuart,McCracken [15]
;
Peter,Ostler [16]
;
Sangeeta,Paisey [17]
;
Angus,Robinson [18]
;
Bhavan,Rai [19]
;
Naveed,Sarwar [14]
;
Narayanan,Srihari [20]
;
Kamal Thippu,Jayaprakash [9]
;
Mohini,Varughese [21]
;
Mathias,Winkler [22]
;
Hashim U,Ahmed [23]
;
Verity,Watson [4]
;
IP5-MATTER Trial Investigators
作者单位：
Imperial Prostate, Division of Surgery, Department of Surgery and Cancer Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. Electronic address: m.connor@imperial.ac.uk.
[1]
Health Economics Research Unit (HERU), Institute of Applied Health Science, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, UK; Newcastle Business School, University of Newcastle, Newcastle, NSW, Australia; Department of Population Health Sciences, Duke University, Durham, USA.
[2]
Urology, University Hospital Southampton, Southampton, UK.
[3]
Health Economics Research Unit (HERU), Institute of Applied Health Science, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, UK.
[4]
Imperial Prostate, Division of Surgery, Department of Surgery and Cancer Imperial College London, London, UK; Imperial College Clinical Trials Unit, Imperial College London, London, UK.
[5]
Department of Oncology, Royal United Hospitals Bath, Bath, UK.
[6]
Department of Oncology and Urology, Medway Maritime Hospital, Kent, UK.
[7]
Department of Oncology, East Surrey Hospital, Redhill, UK.
[8]
Department of Oncology, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust & The Cancer Centre, Addenbrooke's Hospital, Cambridge, UK.
[9]
Department of Oncology, Betsi Cadwaladr University Health Board, Bangor, UK.
[10]
Department of Oncology, The Royal Marsden Hospital, London, UK.
[11]
Imperial College Clinical Trials Unit, Imperial College London, London, UK.
[12]
Department of Urology, Dartford and Gravesham NHS Trust, Kent, UK.
[13]
Department of Oncology, Imperial College Healthcare NHS Trust, London, UK.
[14]
Department of Urology, Sunderland Royal Hospital, Sunderland, UK.
[15]
Department of Oncology, Luton and Dunstable University Hospital, Luton, UK.
[16]
Department of Oncology, Hampshire Hospitals NHS Foundation Trust, Basingstoke and Winchester, UK.
[17]
Department of Oncology, Royal Sussex County Hospital, Brighton, UK.
[18]
Department of Urology, Newcastle Freeman Hospital, Newcastle, UK.
[19]
Department of Oncology, Royal Shrewsbury Hospital, Shrewsbury, UK.
[20]
Department of Oncology, Royal Devon and Exeter NHS Foundation Trust, Oncology, Exeter, UK.
[21]
Imperial Prostate, Division of Surgery, Department of Surgery and Cancer Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; Department of Urology, West Middlesex University Hospital, London, UK.
[22]
Imperial Prostate, Division of Surgery, Department of Surgery and Cancer Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
[23]
DOI
10.1016/j.euo.2024.06.010
PMID
38972831
发布时间
2024-07-07
换一批
换一批
